Primary Category:
Treatment Protocols
Disease Category:
Chronic Lymphocytic Leukemia, Leukemia
Status:
Closed
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) with Chronic Lymphocytic Leukemia (CLL)
NCT#03737981
Eligible for screening study DCP 001
A041702 is closed to accrual, effective July 15, 2022
A041702, Step 1 registration, is closed to accrual, effective November 1, 2022